ClinicalTrials.gg
CompletedNCT05023278Updated Nov 10, 2026Results posted

The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement

A Phase 4 interventional study of Venlafaxine 37.5 MG and Placebo in Acute Pain, Chronic Pain and Knee Pain Chronic, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

How we know

Updated Nov 10, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
140th of 322
100 · median 86
Started
2021
with 30 others
Phase 4
66 of 353
7 open now
Registered
241st of 353
by date

Among the 353 studies in Acute Pain with a site in United States, this one is the 140th largest by enrollment of the 322 interventional ones that give a count, is one of 31 that started in 2021, is one of 66 in phase 4, and was the 241st registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

Patients experience pain after their knee replacement surgery - and some may continue to experience persistent pain long after their knee replacement surgery. Traditional pain management strategies reply on pain medication such as opioids for pain control. However, these drugs do not work well for pain associated with movement or the the nerve pain (tingling, electrical sensations) after surgery. In addition, opioids are associated with significant side effects such as nausea, vomiting, respiratory depression, depression, cognitive dysfunction and risk of persistent opioid use. Neuropathic pain medications, such as venlafaxine are effective in managing nerve pain. Recent studies also support its potential role in acute pain management. Here, we propose a prospective randomized clinical trial 1) to evaluate the efficacy of Venlafaxine in reducing pain intensity and opioid consumption at post-operative day 1 (POD1) and 1- week after surgery, and 2) to examine whether the use of Venlafaxine will reduce the incidents of chronic postsurgical pain in TKA patients at 3-month time point.

Read the detailed description

Patients meeting the inclusion criteria will be randomized to receive either Venlafaxine extended release (ER) 37.5 mg/d or a placebo on the day of surgery and continue the treatment for 7 days after surgery. The primary outcomes include pain severity score (numeric rating scale, NRS) and consumption of morphine miligram equivalent (MME) at 24 hours. The secondary outcome will measure MME and NRS at postoperative day 7. In addition, the disability scale and perceived function 3 months after surgery will be compared to the baseline level by using PROMIS (Patient-Reported Outcomes Measurement Information System)10 Global Health, KOOS, JR. (Knee injury and Osteoarthritis Outcome Score Short Form), and VR-12 (Veterans RAND 12 Item Health Survey) Scale.

03

Conditions studied

  • Acute Pain
  • Chronic Pain
  • Knee Pain Chronic
  • Neuropathic Pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult (male and female) subjects aged 18 to 75,
  • English speaking,
  • are scheduled for primary total knee arthroplasty with planned spinal anesthesia with saphenous peripheral nerve block at the adductor canal.

Exclusion criteria

Exclusion Criteria:

  • general anesthesia,
  • hepatic \& renal failure,
  • history of diabetic peripheral neuropathic pain,
  • chronic opioid use,
  • concurrent use of antidepressants, triptans, and/or linezolid,
  • allergy to the study medications,
  • prior knee surgery,
  • > 40,
  • bleeding disorders,
  • history of recent falls,
  • concurrent benzodiazepine use.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects in placebo arm will receive inactive placebo capsule daily for 7 consecutive days starting on day of primary arthroplasty surgery.

    Drug: Placebo

  • Experimental
    Venlafaxine

    Subjects in venlafaxine arm will receive venlafaxine 37.5mg daily for 7 consecutive days starting on day of primary arthroplasty surgery.

    Drug: Venlafaxine 37.5 MG

Interventions

  • DrugVenlafaxineStudies of VenlafaxineVenlafaxine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    venlafaxine 37.5mg daily for 7 consecutive days.

    Also known as: SNRI analgesia

  • DrugPlacebo

    placebo filled pill daily for 7 consecutive days.

    Also known as: control

06

What researchers measure

Primary outcomes

  1. Total Opioid Consumption on Postoperative Day 1

    Total opioid consumption measured in morphine milligram equivalents (MME) on postoperative day 1.

    Time frame: Postoperative Day 1

Secondary outcomes

  1. NRS Pain Score at Postoperative Day 1

    Pain Scores will be measured on the Numerical Rating Scale (NRS), the score ranges from 0-10, zero indicating no pain and 10 indicating the worst pain.

    Time frame: Postoperative Day 1

  2. BPI Pain Interference Score at Postoperative Day 7

    The Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning.The BPI scale defines pain as follows:1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain.

    Time frame: Postoperative Day 7

  3. Pain Severity and Interference at 3 Months Post Operatively

    The Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning.The BPI scale defines pain as follows:1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain.

    Time frame: 3 months

  4. Opioid Consumption at 7 Days Postoperatively

    morphine miligram equivalent

    Time frame: 7 days

  5. Functionality at 3 Months - KOOS Short Form

    Knee Injury and Osteoarthritis Outcome Score Short Form (KOOS-12), a 12-item patient-reported questionnaire assessing knee-related quality of life. Scored 0-100 where 0 = extreme knee problems and 100 = no knee problems. Higher scores represent better knee function. Values reported as change from baseline to 3 months postoperatively (3-month score minus baseline score); higher change scores indicate greater improvement. Assessed at baseline and 3 months postoperatively.

    Time frame: 3 months

  6. Number of Participants Consuming Opioids at 3 Months

    number of participants who reported consuming opioids at the 3-month follow-up.

    Time frame: 3 months

  7. Patient Satisfaction With Pain Control

    Patient satisfaction with pain control measured on a 0-100 visual analog scale, where 0 = completely dissatisfied and 100 = completely satisfied. Assessed at POD1, POD2, POD7, and 3 months postoperatively. Values represent model-predicted means from mixed-effects repeated measures analysis.

    Time frame: Postoperative Days 1, 2, 7, and 3 months

  8. Functionality at 3 Months - PROMIS Global-10

    PROMIS Global-10 (Patient-Reported Outcomes Measurement Information System), reported as T-scores standardized to the US general population (mean=50, SD=10). Four subscores reported separately: Global Mental Health (GMH), Global Physical Health (GPH), Mental Component Score (MCS), and Physical Component Score (PCS). For all subscores, higher T-scores represent better health outcomes. Values reported as change from baseline to 3 months postoperatively (3-month score minus baseline score); higher change scores indicate greater improvement. Assessed at baseline and 3 months postoperatively.

    Time frame: 3 months

07

Results

Posted Nov 10, 2026
Limitations and caveats
Single-center design limits generalizability. The venlafaxine dose (37.5 mg) predominantly affects serotonin reuptake with minimal norepinephrine inhibition, which may underestimate class effect. Treatment duration of 7 days may be insufficient for full analgesic benefit. Potent baseline multimodal analgesia may have created a ceiling effect on POD1. Patients were not stratified by pain phenotype or central sensitization status.

Participant flow

From May 2021 to March 2025, 408 patients were assessed for eligibility at UCSF Medical Center. Of these, 308 were excluded for not meeting inclusion criteria or declining to participate. One hundred patients provided informed consent and were randomized: 49 to venlafaxine and 51 to placebo.

Participant flow — Overall Study
MilestonePlaceboVenlafaxine
Started3940
Completed3940
Not completed00

Outcome measures

PrimaryTotal Opioid Consumption on Postoperative Day 1

Total opioid consumption measured in morphine milligram equivalents (MME) on postoperative day 1.

Time frame:
Postoperative Day 1
Reported as:
Mean · mg MME
Total Opioid Consumption on Postoperative Day 1
mg MMEPlaceboVenlafaxine
Total Opioid Consumption on Postoperative Day 132.15 ± 30.3023.60 ± 20.44
SecondaryNRS Pain Score at Postoperative Day 1

Pain Scores will be measured on the Numerical Rating Scale (NRS), the score ranges from 0-10, zero indicating no pain and 10 indicating the worst pain.

Time frame:
Postoperative Day 1
Reported as:
Mean · Score (0-10)
NRS Pain Score at Postoperative Day 1
Score (0-10)PlaceboVenlafaxine
NRS Pain Score at Postoperative Day 13.5 ± 2.33.3 ± 2.1
SecondaryBPI Pain Interference Score at Postoperative Day 7

The Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning.The BPI scale defines pain as follows:1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain.

Time frame:
Postoperative Day 7
Reported as:
Mean · Score (0-10)
BPI Pain Interference Score at Postoperative Day 7
Score (0-10)PlaceboVenlafaxine
BPI Pain Interference Score at Postoperative Day 73.5 ± 2.13.2 ± 2.0
SecondaryPain Severity and Interference at 3 Months Post Operatively

The Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning.The BPI scale defines pain as follows:1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain.

Time frame:
3 months
Reported as:
Mean · Score (0-10)
Pain Severity and Interference at 3 Months Post Operatively
Score (0-10)PlaceboVenlafaxine
Pain Severity and Interference at 3 Months Post Operatively1.5 ± 2.20.9 ± 1.6
SecondaryOpioid Consumption at 7 Days Postoperatively

morphine miligram equivalent

Time frame:
7 days
Reported as:
Mean · morphine milligram equivalents (MME)
Opioid Consumption at 7 Days Postoperatively
morphine milligram equivalents (MME)PlaceboVenlafaxine
Opioid Consumption at 7 Days Postoperatively33.67 (22.48 to 42.57)18.65 (9.84 to 27.46)
SecondaryFunctionality at 3 Months - KOOS Short Form

Knee Injury and Osteoarthritis Outcome Score Short Form (KOOS-12), a 12-item patient-reported questionnaire assessing knee-related quality of life. Scored 0-100 where 0 = extreme knee problems and 100 = no knee problems. Higher scores represent better knee function. Values reported as change from baseline to 3 months postoperatively (3-month score minus baseline score); higher change scores indicate greater improvement. Assessed at baseline and 3 months postoperatively.

Time frame:
3 months
Reported as:
Mean · score change from baseline
Functionality at 3 Months - KOOS Short Form
score change from baselinePlaceboVenlafaxine
Functionality at 3 Months - KOOS Short Form16.3 ± 13.822.9 ± 17.5
SecondaryNumber of Participants Consuming Opioids at 3 Months

number of participants who reported consuming opioids at the 3-month follow-up.

Time frame:
3 months
Reported as:
Number · Number of patients
Number of Participants Consuming Opioids at 3 Months
Number of patientsPlaceboVenlafaxine
Number of Participants Consuming Opioids at 3 Months21
SecondaryPatient Satisfaction With Pain Control

Patient satisfaction with pain control measured on a 0-100 visual analog scale, where 0 = completely dissatisfied and 100 = completely satisfied. Assessed at POD1, POD2, POD7, and 3 months postoperatively. Values represent model-predicted means from mixed-effects repeated measures analysis.

Time frame:
Postoperative Days 1, 2, 7, and 3 months
Reported as:
Mean · score (0-100 VAS)
Patient Satisfaction With Pain Control
score (0-100 VAS)PlaceboVenlafaxine
Satisfaction score with Pain Control on POD178.6 (71.2 to 86.0)80.8 (73.2 to 88.5)
Satisfaction score with Pain Control on POD259.1 (51.8 to 66.4)69.8 (62.4 to 77.2)
Satisfaction score with Pain Control on POD761.0 (53.6 to 68.3)74.6 (67.3 to 82.0)
Satisfaction score with Pain Control at 3 months74.1 (66.5 to 81.7)89.6 (81.5 to 97.6)
SecondaryFunctionality at 3 Months - PROMIS Global-10

PROMIS Global-10 (Patient-Reported Outcomes Measurement Information System), reported as T-scores standardized to the US general population (mean=50, SD=10). Four subscores reported separately: Global Mental Health (GMH), Global Physical Health (GPH), Mental Component Score (MCS), and Physical Component Score (PCS). For all subscores, higher T-scores represent better health outcomes. Values reported as change from baseline to 3 months postoperatively (3-month score minus baseline score); higher change scores indicate greater improvement. Assessed at baseline and 3 months postoperatively.

Time frame:
3 months
Reported as:
Mean · T-score
Functionality at 3 Months - PROMIS Global-10
T-scorePlaceboVenlafaxine
PROMIS GMH change0.9 ± 7.13.6 ± 5.2
PROMIS GPH change5.7 ± 7.17.5 ± 6.0
PROMIS MCS change-1.6 ± 9.7-0.2 ± 8.4
PROMIS PCS change8.3 ± 10.011.9 ± 10.2

Adverse events

Collected over From first dose of study medication through postoperative day 7 (duration of study drug administration). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/38 (0%)0/38 (0%)0/38 (0%)
Venlafaxine0/39 (0%)0/39 (0%)0/39 (0%)

Baseline characteristics

Per-protocol population of 79 patients who received the allocated intervention and underwent primary total knee arthroplasty (40 venlafaxine, 39 placebo).

Age, Continuous
Age, Continuous(Years)PlaceboVenlafaxineTotal
Mean67.0 ± 6.766 ± 9.966.5 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVenlafaxineTotal
Female221941
Male172138
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)PlaceboVenlafaxineTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)PlaceboVenlafaxineTotal
United States394079
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)PlaceboVenlafaxineTotal
Mean28.5 ± 5.629.4 ± 4.129.0 ± 4.9
Baseline NRS Pain Score
Baseline NRS Pain Score(Score (0-10))PlaceboVenlafaxineTotal
Mean3.7 ± 2.24.1 ± 1.83.9 ± 2.0
08

Study locations

1 site
  • University of California San Francisco
    San Francisco, California 94143, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share our raw clinical data with other researchers.

Supporting information: Study protocol

Time frame: For the entire study period

Access criteria: Non-profit and research purpose.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Feb 2025, 45 months.

Results were first posted in Nov 2026, 1 year 8 months after primary completion.

Of 79 non-industry phase 4 interventional studies under Acute Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 32. This study's 45 months is above that.

Counting every sponsor, half of 84 studies reached it within 19 months; a quarter within 9 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2021
First posted
Aug 26, 2021
StartActual
May 10, 2021
Primary completionActual
Feb 28, 2025
CompletionActual
Mar 31, 2025
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Cumulative 24 hour total opioid consumptionNow Total Opioid Consumption on Postoperative Day 1Time frame: 24 hours → Postoperative Day 1
Nov 10, 2026
Documents
Secondary outcomes
6 edited, 2 added, 3 removed
What changed in the outcomes
  • EditedPain severitySeverity and interferenceInterference at 7 days post operatively3 Months Post OperativelyTime frame: 7 days → 3 months
  • EditedFunctionalityOpioid Consumption at 7 days postoperativelyDays PostoperativelyTime frame: 7 days
  • EditedFunctionality at 3 months postoperativelyMonths - KOOS Short FormTime frame: 3 months
  • EditedFunctionality at 3 months postoperativelyMonths - PROMIS Global-10Time frame: 3 months
  • ChangedBefore Pain numeric rating scale at 24 hours post operativelyNow NRS Pain Score at Postoperative Day 1Time frame: 24 hours → Postoperative Day 1
  • ChangedBefore Pain severity and interference at 3 months post operativelyNow BPI Pain Interference Score at Postoperative Day 7Time frame: 3 months → Postoperative Day 7
  • AddedNumber of Participants Consuming Opioids at 3 MonthsTime frame: 3 months
  • AddedPatient Satisfaction With Pain ControlTime frame: Postoperative Days 1, 2, 7, and 3 months
  • RemovedFunctionality at 7 days postoperativelyTime frame: 7 days
  • RemovedOpioid consumption at 7 days postoperativelyTime frame: 7 days
  • RemovedOpioid consumption at 3 months postoperativelyTime frame: 3 months
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Cumulative 24 hour total opioid consumptionNow Total Opioid Consumption on Postoperative Day 1Time frame: 24 hours → Postoperative Day 1
    Secondary outcomes 6 edited, 2 added, 3 removed
    What changed in the outcomes
    • EditedPain severitySeverity and interferenceInterference at 7 days post operatively3 Months Post OperativelyTime frame: 7 days → 3 months
    • EditedFunctionalityOpioid Consumption at 7 days postoperativelyDays PostoperativelyTime frame: 7 days
    • EditedFunctionality at 3 months postoperativelyMonths - KOOS Short FormTime frame: 3 months
    • EditedFunctionality at 3 months postoperativelyMonths - PROMIS Global-10Time frame: 3 months
    • ChangedBefore Pain numeric rating scale at 24 hours post operativelyNow NRS Pain Score at Postoperative Day 1Time frame: 24 hours → Postoperative Day 1
    • ChangedBefore Pain severity and interference at 3 months post operativelyNow BPI Pain Interference Score at Postoperative Day 7Time frame: 3 months → Postoperative Day 7
    • AddedNumber of Participants Consuming Opioids at 3 MonthsTime frame: 3 months
    • AddedPatient Satisfaction With Pain ControlTime frame: Postoperative Days 1, 2, 7, and 3 months
    • RemovedFunctionality at 7 days postoperativelyTime frame: 7 days
    • RemovedOpioid consumption at 7 days postoperativelyTime frame: 7 days
    • RemovedOpioid consumption at 3 months postoperativelyTime frame: 3 months
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05023278
Collaborators
Orthopedic Research and Education Foundation
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
May 10, 2021
Primary completion
Feb 28, 2025
Completion
Mar 31, 2025
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Matthias Behrends, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venlafaxine

Start the discussion